Rationale: Naturally occurring mutations in the cardiac ryanodine receptor (RyR2) have been associated with both cardiac arrhythmias and cardiomyopathies. It is clear that delayed afterdepolarization resulting from abnormal activation of sarcoplasmic reticulum Ca 2؉ release is the primary cause of RyR2-associated cardiac arrhythmias. However, the mechanism underlying RyR2-associated cardiomyopathies is completely unknown.
T he cardiac ryanodine receptor (RyR2) is the major Ca 2ϩ release channel of the sarcoplasmic reticulum (SR) and plays an essential role in excitation-contraction coupling and SR Ca 2ϩ homeostasis. 1 Abnormal SR Ca 2ϩ handling attributable to defective RyR2 function is a well-known cause of ventricular tachyarrhythmias and sudden death. 2, 3 Naturally occurring RyR2 mutations have been linked to catecholaminergic polymorphic ventricular tachycardia (CPVT) and catecholaminergic idiopathic ventricular fibrillation. 4 -6 More than 150 disease-associated RyR2 mutations have been identified to date. 6, 7 Most of these RyR2 mutations are associated with stress-induced ventricular tachyarrhythmias and sudden death in structurally normal hearts. However, some of them are associated with cardiomyopathies as well as cardiac arrhythmias. 6, 7 For example, an in-frame deletion of 35 amino acid residues (Asn57-Gly91) in the NH 2terminal region, corresponding to exon-3 of the RYR2 gene, was identified in several unrelated families. This deletion is associated with an expanding spectrum of phenotypes that include sinoatrial nodal dysfunction, atrial fibrillation, atrioventricular block, decreased left ventricular function, increased trabeculation, CPVT, and dilated cardiomyopathy (DCM). [7] [8] [9] Furthermore, a number of RyR2 NH 2 -terminal point mutations, including A77V, R176Q/T2504M, R420W, and L433P, are associated with arrhythmogenic right ventricular displasia type 2 (ARVD2). 6,7,10 -14 RyR2 mutations also may be associated with hypertrophic cardiomyopathy (HCM). 15 A definitive link be-tween RyR2 mutations and a specific type of cardiomyopathy has not been firmly established because of the small number of RyR2 mutation carriers and their variable clinical phenotypes. However, an increasing body of evidence suggests that defective RyR2 function can lead not only to cardiac arrhythmias but also to cardiomyopathies.
An important question is how the various RyR2 mutations produce all the different phenotypes. One possibility is that different RyR2 mutations may alter different aspects of SR Ca 2ϩ release. The initiation/activation of SR Ca 2ϩ release is normally well-controlled by membrane depolarization via a mechanism known as Ca 2ϩ -induced Ca 2ϩ release. 1 Under conditions of SR Ca 2ϩ overload, however, SR Ca 2ϩ release in the form of Ca 2ϩ waves can occur spontaneously in the absence of membrane depolarization. 3,16 -21 These spontaneous Ca 2ϩ waves, also termed store overload-induced Ca 2ϩ release (SOICR), 22, 23 may result in delayed afterdepolarizations (DADs) and triggered arrhythmia. 2, 3, 20 We have recently demonstrated that a number of RyR2 mutations associated with CPVT reduce the threshold for SOICR. 22, 23 A reduced SOICR threshold will increase the propensity for DADs and, thus, triggered arrhythmias. Therefore, abnormal activation of Ca 2ϩ release attributable to inappropriate opening of RyR2 represents a common mechanism for RyR2-associated CPVT. 6 The mechanism for RyR2-associated cardiomyopathies remains unknown. Recent studies demonstrate that SR Ca 2ϩ stores are only partially depleted during local or depolarization-induced global Ca 2ϩ transients, 24 -26 indicating that SR Ca 2ϩ release terminates well before the store is empty. The process that terminates Ca 2ϩ release is thought to be critical for maintaining stable excitation-contraction coupling and controlling the cytosolic Ca 2ϩ transient. [27] [28] [29] [30] Abnormal cytosolic Ca 2ϩ transients have been proposed to trigger the cardiac remodeling 31, 32 associated with cardiomyopathies. [33] [34] [35] It is therefore possible that RyR2 mutations associated with cardiomyopathies may alter the process of Ca 2ϩ release termination. To test this possibility, we assessed the impact on Ca 2ϩ release of a number of NH 2 -terminal RyR2 mutations that are associated with cardiomyopathies. We report that the NH 2 -terminal region of RyR2 is an important determinant of Ca 2ϩ release termination. Further, we show that altered Ca 2ϩ release termination is a common defect of RyR2 mutations associated with cardiomyopathies.
Methods

Site-Directed Mutagenesis and DNA Transfection
All RyR2 mutations were generated using the overlap extension method as previously described. 23, 36 HL-1 cardiac cells were transfected with the GFP-tagged RyR2 wild-type (WT) or the GFP-tagged RyR2 mutant, Del-Exon-3, using the Nucleofector kit (Amaxa) according to the manufacturer's instructions.
Generation of Stable Inducible HEK293 Cell Lines Expressing RyR2 WT and Mutants
Stable inducible HEK293 cell lines expressing RyR2 WT or mutants were generated using the Flp-In T-REx Core kit (Invitrogen Life Technologies) according to the manufacturer's instructions.
Single-Cell Ca 2؉ Imaging
Luminal Ca 2ϩ transients in HEK293 cells expressing RyR2 WT or mutant channels were measured using the Ca 2ϩ -sensitive fluorescence resonance energy transfer (FRET)-based cameleon protein D1ER. 37, 38 Stable inducible HEK293 cells were transfected with the D1ER cDNA 24 hours before the induction of RyR2 expression. Fluorescent images were captured using an inverted microscope (Nikon TE2000-S) with S-Fluor 20ϫ/0.75 objective. The amount of FRET was determined from the ratio of the emissions at 535 and 470 nm (excitation at 430 nm). Cytosolic Ca 2ϩ transients in these cells were monitored using the fluorescent Ca 2ϩ indicator dye Fura-2 acetoxymethyl ester as previously described. 22, 23 Time-lapse images (0.5 frame/s) were captured and analyzed with the Compix Simple PCI 6 software (Compix). Fluorescence intensities were measured from regions of interest centered on individual cells.
Detailed Methods are provided in the Online Supplement.
Results
The NH 2 -Terminal Region of RyR2 Is an Important Determinant of Ca 2؉ Release Termination
There are more than 20 disease-causing mutations in the NH 2 -terminal region of RyR2. 6, 7 The functional role of this region and the consequences of these mutations are unclear.
To gain insights into these unknowns, we used a deletion approach in which we removed the first 305 NH 2 -terminal residues of RyR2 (Del-305) (Online Figure I ). Ca 2ϩ release assays and immunoblotting analysis revealed that the Del-305 mutant was expressed in HEK293 cells and remained functional (Online Figure IB , IC). Thus, deletion of the first 305 NH 2 -terminal residues of RyR2 did not abolish its expression or function. We used a FRET-based endoplasmic reticulum (ER) luminal Ca 2ϩ -sensing protein D1ER 37 to monitor the ER luminal Ca 2ϩ dynamics and to determine whether the NH 2 -terminal deletion alters SOICR. As shown in Figure 1 , elevating extracellular Ca 2ϩ from 0 to 2 mmol/L induced SOICR in HEK293 cells expressing RyR2 WT (observed as the downward deflections of the FRET signal; Figure 1A ). SOICR occurred when the ER Ca 2ϩ increased to a threshold level (the SOICR activation threshold, F SOICR ) and terminated when the ER Ca 2ϩ declined to another threshold level (the SOICR termination threshold, F termi ; Figure 1A ). This SOICR in HEK293 cells expressing RyR2 WT terminated at a threshold of 57% store capacity, which is similar to that (60%) observed in cardiomyocytes. 26 
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Note that SOICR is mediated by RyR2, not by any endogenous inositol-1,4,5-trisphosphate receptors (IP3Rs) that may be present, because xestospongin C, an inhibitor of IP3Rs, had no effect on SOICR in HEK293 cells expressing RyR2 WT (Online Figure II) . SOICR was also observed in HEK293 cells expressing the RyR2 Del-305 mutant ( Figure 1B ). The SOICR in the Del-305 mutant cells exhibited a marked reduction in the termination threshold (35% vs 57% in WT; PϽ0.01) and a slightly lowered activation threshold (90% vs 94% in WT; PϽ0.01; Figure 1C , 1D). As a result, the fractional Ca 2ϩ release during SOICR (activation threshold Ϫ termination threshold) is significantly greater in the Del-305 cells (55%) than in the WT cells (36%; PϽ0.01; Figure 1E ). There were no significant differences in the maximum FRET signal (F max ) obtained after tetracaine treatment, the minimum FRET signal (F min ) obtained after 20 mmol/L caffeine application, or the store capacity (F max Ϫ F min ) between the WT and Del-305 mutant cells ( Figure 1F -H). Note that the D1ER probe was not saturated in HEK293 cells (data not shown), similar to that reported previously. 39 These studies show that the NH 2 -terminal region of RyR2 has an important role in the termination of Ca 2ϩ release.
Deletion of Exon-3 in RyR2 Reduces the Threshold for Ca 2؉ Release Termination
We next determined whether the cardiomyopathy-associated deletion of exon-3 (Del-exon-3) within the NH 2 -terminal Figure III shows that the Del-exon-3 mutant formed functional RyR2s in HEK293 cells (Online Figure IIIB) and was expressed at a level similar to that of RyR2 WT (Online Figure IIIC) . The ER luminal Ca 2ϩ dynamics in these Del-exon-3 cells was assessed. SOICR in the Del-exon-3 cells had a slightly lower activation threshold (88% vs 94% in WT; PϽ0.01) and a markedly reduced termination threshold (39% vs 57% in WT; PϽ0.01; Figure 2A -D). The fractional Ca 2ϩ release in the Del-exon-3 cells (49%) was also significantly greater than in the WT cells (36%; PϽ0.01; Figure  2E ). There were no significant differences in F max , F min , or store capacity between the WT and Del-Exon-3 cells ( Figure  2F -H). These results demonstrate that the cardiomyopathyassociated exon-3 deletion in RyR2 reduces the threshold for Ca 2ϩ release termination and increases fractional release in HEK293 cells.
Exon-3 Deletion Enhances the Propensity for SOICR and the Magnitude of Ca 2؉ Transients
A reduced termination threshold would increase the magnitude of Ca 2ϩ release into the cytosol. To directly test this, we monitored the cytosolic Ca 2ϩ transient using the cytosolic Ca 2ϩ dye, Fura-2 acetoxymethyl ester. In both the WT ( Figure 3A) and Del-Exon-3 ( Figure 3B ) cells, increasing extracellular Ca 2ϩ induced SOICR observed as oscillatory cytosolic Ca 2ϩ transients. Importantly, the Del-exon-3 mutation increased the propensity ( Figure 3C ), amplitude (127%Ϯ1.3% of WT; PϽ0.05; Figure 3D ), and frequency (108%Ϯ2.2% of WT; PϽ0.05; Figure 3E ) of SOICR. Simi- larly, we found that the Del-305 deletion also enhanced the propensity and amplitude of SOICR (Online Figure IV) . Note that the store Ca 2ϩ contents in the RyR2 WT (100%), Del-exon-3 (98%Ϯ1.0% of WT), and Del-305 (104%Ϯ3.9% of WT) cells were not significantly different.
To determine whether the Del-exon-3 deletion alters SOICR in cardiac cells, we transfected the HL-1 cardiac cells (a mouse atrial cell line) with the GFP-tagged RyR2 WT or GFP-tagged Del-exon-3 mutant. Cytosolic Ca 2ϩ transients indicative of SOICR are shown in Figure 4 . The Del-exon-3 deletion significantly increased the occurrence ( Figure 4C ) and amplitude (193%Ϯ1.0% of WT; PϽ0.01; Figure 4D ), but not the frequency (133%Ϯ13% of WT; Pϭ0.06; Figure 4E ) of SOICR in HL-1 cardiac cells. There was no significant difference in the store Ca 2ϩ contents between the WT (100%) and Del-exon-3 (104%Ϯ1.0% of WT; Pϭ0.74) transfected HL-1 cardiac cells. Overall, these results suggest that the cardiomyopthy-associated exon-3 deletion promotes SOICR by reducing its activation threshold and increases the amplitude of Ca 2ϩ release (fractional release) by reducing its termination threshold.
RyR2 NH 2 -Terminal Mutations Associated With ARVD2 Reduce the Threshold for Ca 2؉ Release Termination
A number of point mutations in the NH 2 -terminal region of RyR2 are associated with ARVD2 cardiomyopathy. 6,7,10 -14 To determine whether these NH 2 -terminal ARVD2associated RyR2 mutations also affect Ca 2ϩ release termination, we generated HEK293 cell lines that express the RyR2 mutations, A77V, R176Q/T2504M, R420W, and L433P. As shown in Figure 5 , each of these RyR2 mutations reduced the SOICR activation ( Figure 5A ) and termination ( Figure 5B ) thresholds. Each mutation also increased the fractional Ca 2ϩ release because of a greater reduction in the termination threshold than in the activation threshold ( Figure 5C ). Interestingly, CPVT mutations E189D and R4496C that are not associated with cardiomyopathy 40, 41 reduced the activation and termination thresholds to a similar extent ( Figure 5A, B) . As a result, this mutation did not significantly alter fractional release ( Figure 5C ). There were no significant differences in F max , F min , or store capacity between WT and any of these mutant cells (Online Figure V) . Also, all these mutants were expressed in HEK293 cells at a level comparable to that of WT ( Figure 5D ). Together, these data show that increased fractional Ca 2ϩ release attributable to reduced Ca 2ϩ release termination is a common defect of ARVD2-associated RyR2 mutations.
The Mouse RyR2 A1107M Mutation Increases the Threshold for Ca 2؉ Release Termination
The human RyR2 T1107M mutation is associated with HCM. 15 We generated a stable inducible HEK293 cell line expressing the mouse RyR2 A1107M mutation, which corresponds to the human HCM-associated RyR2 T1107M mutation. Interestingly, the A1107M mutation significantly increased the termination threshold (61% vs 57% in WT; PϽ0.05), but it did not significantly affect the activation threshold ( Figure 6A-C) . This resulted in a significant reduction in the fractional Ca 2ϩ release (32% vs 36% in WT; PϽ0.01; Figure 6D ). There were no significant differences in F max , F min , and store capacity between the WT and A1107M mutant cells ( Figure 6E-G) . The expression levels of the RyR2 WT and A1107M mutant were similar ( Figure 6H ). Therefore, in contrast to the RyR2 mutations associated with DCM and ARVD2, the A1107M mutation associated with HCM increases the threshold for Ca 2ϩ release termination and decreases the fractional Ca 2ϩ release.
Discussion
Mutations in RyR2 are associated with stress-induced ventricular tachyarrhythmias and cardiomyopathies. Extensive investigations over the past decade have demonstrated that spontaneous Ca 2ϩ wave (SOICR)-evoked DADs are the major cause of RyR2-associated CPVT. 4 -6 We and others have shown that CPVT RyR2 mutations reduce the threshold for SOICR. 22, 23, 40, [42] [43] [44] [45] This reduced SOICR threshold increases the likelihood of spontaneous SR Ca 2ϩ release during SR Ca 2ϩ overload and, thus, the likelihood of SOICR-evoked DADs and triggered arrhythmias. 3,16 -21 In contrast, it is unclear how RyR2 mutations lead to cardiomyopathies. We show here that the DCM-associated RyR2 exon-3 deletion and several ARVD2-associated RyR2 NH 2 -terminal mutations (A77V, R176Q/T2504M, R420W, and L433P) all reduce the threshold for Ca 2ϩ release termination, whereas an HCM-associated RyR2 mutation (A1107M) increases the termination threshold. These data demonstrate for the first time to our knowledge that RyR2 mutations associated with cardiomyopathies alter the termination of Ca 2ϩ release.
The exact mechanism by which SR Ca 2ϩ release is terminated remains unclear. Localized SR luminal Ca 2ϩdependent inactivation of RyR2 is likely to be involved. 24, 26, 29, 46, 47 Elegant studies by Zima et al 26 showed that spontaneous (diastolic) and stimulated (systolic) SR Ca 2ϩ release in cardiomyocytes terminate at the same SR luminal Ca 2ϩ threshold. This implies that systolic and diastolic Ca 2ϩ release is terminated by a similar process. We demonstrate here that cardiomyopathy-associated RyR2 mutations alter the termination threshold of SOICR or spontaneous Ca 2ϩ Figure 4 . Effect of the cardiac ryanodine receptor (RyR2) exon-3 deletion on store overloadinduced Ca 2؉ release (SOICR) in mouse HL-1 cardiac cells. Mouse HL-1 cardiac cells were transfected with a GFP-tagged RyR2 wild-type (WT) or a GFP-tagged Del-exon-3 mutant using the Nucleofection method (Amaxa). Transfected cells were loaded with 5 mol/L Fura-2 acetoxymethyl ester (Fura-2 AM) and were then perfused continuously with KRH buffer containing increasing levels of extracellular Ca 2ϩ (0.3-5 mmol/L). Fura-2 ratios of representative HL-1 cardiac cells expressing the GFP-tagged RyR2 WT (A) and the GFPtagged Del-exon-3 mutant (B), identified based on their GFP fluorescence, were recorded using single-cell Ca 2ϩ imaging. C, The percentages of the GFP-tagged RyR2 WT (142) and GFP-tagged Del-exon-3 (153) cells that display Ca 2ϩ oscillations at various extracellular Ca 2ϩ concentrations. SOICR amplitude (D) and frequency (E) in the GFP-tagged RyR2 WT and GFP-tagged Delexon-3 cells were determined by measuring the averaged peak amplitude and frequency of Ca 2ϩ oscillations at 5 mmol/L extracellular Ca 2ϩ and normalized to that in the GFP-tagged RyR2 WT cells (100%). Data shown are meanϮstandard error of the mean (SEM; nϭ6 -8). # PϽ0.05. *PϽ0.01 vs WT.
release. Based on the finding of Zima et al, 26 these RyR2 mutations are likely to alter the termination threshold of systolic Ca 2ϩ release. Furthermore, Zima et al 26 showed that spontaneous SR Ca 2ϩ release terminates when luminal Ca 2ϩ decreases to approximately 60% of the original SR Ca 2ϩ content. Interestingly, we found that SOICR in HEK293 cells expressing RyR2 WT terminates when luminal Ca 2ϩ decreases to approximately 57% of the ER store capacity. The similarity of these termination thresholds could be coincidental. It could also indicate that the termination of Ca 2ϩ release is an intrinsic property of the RyR2 channel. The latter is consistent with the various RyR2 mutations differentially shifting the termination threshold.
An important question is how abnormal termination of Ca 2ϩ release could lead to cardiomyopathies. Cardiomyopa-thies are generally associated with mutations in sarcomeric proteins. Most disease-associated sarcomeric mutations alter the sensitivity of myofilaments to Ca 2ϩ . 33, 35, 48, 49 Because the myofilaments represent a major pool of intracellular Ca 2ϩ binding sites, changes in the Ca 2ϩ sensitivity of myofilaments can alter their response to Ca 2ϩ release, which can, in turn, change the amplitude and dynamics of the cytosolic Ca 2ϩ transient (but not the total release of Ca 2ϩ ). 35, 48, 49 HCMassociated sarcomeric mutations tend to increase the myofilament Ca 2ϩ sensitivity and thus reduce cytosolic Ca 2ϩ transients. However, DCM-associated sarcomeric mutations tend to decrease the myofilament Ca 2ϩ sensitivity and thus increase cytosolic Ca 2ϩ transients. 33, 35, 48, 49 The abnormal cytosolic Ca 2ϩ transient resulting from altered myofilament Ca 2ϩ sensitivity is thought to trigger the cardiac remodeling (via Ca 2ϩ /calmodulin-dependent signaling pathways, the calcineurin/NFAT pathways, or apoptotic signaling) that can lead to HCM or DCM. [31] [32] [33] [34] [35] 50 Abnormal cytosolic Ca 2ϩ transients also could result from altered Ca 2ϩ release termination. A reduced termination threshold would delay the termination of SR Ca 2ϩ release and thus increase the cytosolic Ca 2ϩ transient. An increased termination threshold would cause premature termination of Ca 2ϩ release and consequently would limit the size of the cytosolic Ca 2ϩ transient. Here, we show that a DCMassociated RyR2 mutation reduces the termination threshold and increases the fractional Ca 2ϩ release, whereas an HCMassociated RyR2 mutation increases the termination threshold and decreases fractional release. These changes in fractional release may alter cytosolic Ca 2ϩ transients. These effects are similar to those of sarcomeric mutations associated with DCM and HCM. It is important to note that the fractional Ca 2ϩ release is determined by both the termination and activation thresholds. We show that CPVT-only RyR2 mutations (E189D and R4496C) reduce the activation and termination thresholds to a similar extent, resulting in no significant changes in the fractional Ca 2ϩ release. Therefore, our data suggest a link between abnormal fractional Ca 2ϩ release resulting from aberrant Ca 2ϩ release termination and RyR2associated cardiomyopathies.
Aberrant Ca 2ϩ release termination may also contribute to CPVT. It has been estimated that a diastolic Ca 2ϩ wave (SOICR) that liberates 50% to 70% SR Ca 2ϩ content is required to produce DADs of sufficient amplitude to induce triggered arrhythmias. 51 A reduced termination threshold would increase the fractional Ca 2ϩ release and, thus, the amplitude of Ca 2ϩ waves during SR Ca 2ϩ overload. Larger Ca 2ϩ waves would, in turn, produce more robust DADs and enhance the propensity for triggered activities. Thus, the reduced termination threshold for SOICR of the DCM-associated and ARVD2-associated RyR2 mutations combined with their lowered SOICR activation threshold may explain why these mutations also enhance the susceptibility to CPVT.
The recently solved three-dimensional structures of the NH 2 -terminal region of RyR 52-55 have provided some new insights into how mutations in the NH 2 -terminal region of RyR2 alter Ca 2ϩ release termination. The NH 2 -terminal region of RyR contains three domains that interact with each other to form a cytoplasmic vestibule at the center of the channel. Many disease-causing RyR mutations are located in interfaces between these three domains or between these domains and other parts of the channel. 54 Interestingly, the cytoplasmic vestibule formed by the NH 2 -terminal domains undergoes conformational changes during channel gating. 56 It has been proposed that the NH 2 -terminal domains are allosterically coupled to the transmembrane pore forming domains of the channel. 55 Therefore, mutations in the NH 2 -terminal region may affect the gating of the channel and, thus, Ca 2ϩ release by altering the allosteric coupling between the NH 2terminal domains and the channel pore forming domains. These structural studies also suggest that in addition to the NH 2 -teminal domains, other regions of RyR2 are likely involved in Ca 2ϩ release termination.
The importance of Ca 2ϩ release termination in cardiac physiology and pathophysiology has become increasingly clear. 27, 29, 30 Besides the link between cardiomyopathies and abnormal Ca 2ϩ release termination established here, reduced Ca 2ϩ release termination threshold also has been shown in heart failure. 28, 57 This suggests that, like activation of Ca 2ϩ release, termination of Ca 2ϩ release is also an important target of regulation. Aberrant Ca 2ϩ release termination may be a common defect associated with cardiomyopathies and other cardiac abnormalities.
Limitations
Our studies in HEK293 cells demonstrate that cardiomyopathy-associated RyR2 mutations alter the termination of Ca 2ϩ release. However, HEK293 cells lack many cardiac-specific proteins, and thus the Ca 2ϩ release termination defects of cardiomyopathy-associated RyR2 mutations have yet to be confirmed in cardiac cells. At the moment, such studies would require the development of mouse models harboring cardiomyopathy-associated RyR2 mutations. These animal models are presently unavailable. Our studies also do not define the molecular mechanisms underlying the activation/ termination thresholds or how these might be regulated by various proteins (eg, calsequestrin) and factors (eg, cytosolic or luminal Ca 2ϩ ). Further comprehensive and detailed investigations will be required to address these important issues. (250) and the A1107M mutant (111) cells were determined as described in Figure 1 . Data shown are meanϮstandard error of the mean (SEM; nϭ7-13). # PϽ0.05 and *PϽ0.01 vs wild-type (WT). H, Immunoblotting of RyR2 WT and the A1107M mutant from the same amount of cell lysates using the anti-RyR antibody (34c; nϭ3). Note that the images were from the same gel. 
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